TrialThe oncologist2022

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).

Yasuyuki Kawamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.